PhRMA/BIO Devise 'Principles' To End Off-Label Limbo
Tired of waiting for safe harbor protections about communicating to payers and prescribers about pharmacoeconomics and unapproved uses, PhRMA and BIO are trying to move discussion forward.
Tired of waiting for safe harbor protections about communicating to payers and prescribers about pharmacoeconomics and unapproved uses, PhRMA and BIO are trying to move discussion forward.